Dscam Reveals its Bountiful Plan

Courtesy of Dietmar SchumuckerI got this cDNA sequence alignment for the Dscam gene in October 1999 while working in Larry Zipursky's lab. The gap in the alignment hinted at alternative splicing of the transmembrane domain. But that was just the tip of the iceberg: The handwritten inset is from my notes indicating not only this successful sequencing reaction but also that two reactions failed – much to my frustration (see the question marks). It turned out, however, that this was good news

Written byDietmar Schmuchker
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Courtesy of Dietmar Schumucker

I got this cDNA sequence alignment for the Dscam gene in October 1999 while working in Larry Zipursky's lab. The gap in the alignment hinted at alternative splicing of the transmembrane domain. But that was just the tip of the iceberg: The handwritten inset is from my notes indicating not only this successful sequencing reaction but also that two reactions failed – much to my frustration (see the question marks). It turned out, however, that this was good news.

Serendipitously, I had designed sequencing primers that were located in the other variable regions of Dscam and therefore could only work in one cDNA. Based on this and the newly published Drosophila genome sequence, Jim Clemans, Huidy Shu, and myself were able to work out the mystery over the following few weeks. Six months later we reported1 that Dscam could be alternatively spliced into 38,016 different protein ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies